开发心脏瘤功能基因组学平台,使人类TNNT2变种的可扩展查询成为可能
Anthony M Pettinato1, Feria A Ladha1, David J Mellert2
1University of Connecticut Health Center (A.M.P., F.A.L., R.R., J.T.H.).
Circulation
|October 7, 2020
概括
致病性TNNT2变体会影响心肌收缩,导致心肌缩或扩张性心肌病. 这项研究开发了评估变异效应的新方法,改善了疾病风险预测和对心力衰竭的理解.
科学领域:
- 心血管遗传学
- 分子心脏病学
- 干细胞生物学
背景情况:
- 致病性TNNT2变体与高和扩张性心肌病有关,导致心力衰竭的机制尚不清楚.
- 由于功能基因组学研究有限,大多数TNNT2变体的功能影响尚不清楚.
- 了解TNNT2变体的影响对于改善心力衰竭风险评估,治疗和发现新的治疗点至关重要.
研究的目的:
- 开发和应用人类诱导多能干细胞 (hiPSC) 模型和功能测试工具包,以调查TNNT2变异的致病性和病理生理学.
- 在心脏微组织和单细胞测试中使用hiPSC衍生心肌细胞对51种TNNT2变异进行功能评估.
- 利用RNA测序和开发CRISPR工程转录记者试验来预测TNNT2变体的致病性.
主要方法:
- 创建了使用CRISPR/Cas9进行TNNT2变体研究的hiPSC模型和功能测试.
- 在使用心脏微组织和单细胞测试的hiPSC衍生心肌细胞中对51种TNNT2变异进行了功能性调查.
- 采用RNA测序来分析转录基因后果,并开发了一种用于病原性预测的记者测试,以及记者测试.
主要成果:
- 与缩性心肌病相关的TNNT2变体增加了心脏微组织收缩,而扩张性心肌病变体减少了它.
- 癌细胞功能变异与101个基因的转录基因变异相关,包括MAPK信号标,HOPX和NPPB.
- 结合NPPB表达和收缩数据的报告测试支持了四种TNNT2变体的重新分类.
结论:
- 过敏心肌病相关的TNNT2变体增强了收缩,而扩张心肌病变体减少了收缩,反映了肌纤维亲和度的变化.
- 转录组变化,特别是NPPB水平,与瘤功能相关,可以预测TNNT2变异的致病性.
- 这项研究为TNNT2变体的功能评估提供了框架,有助于心肌病的诊断和理解.
更多相关视频
08:37Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.
Published on: March 3, 2021
4.8K
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
4.0K
相关概念视频
Genomics
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
